Implicazioni economiche del trattamento dei pazienti emofilici con inibitori: Una revisione sistematica della letteratura

Translated title of the contribution: Economic implications of treating patients with hemophilia and inhibitors: A systematic literature review

Cristina Negrini, F. Daniele, M. E. Mancuso, G. F. Rivolta, A. Tagliaferri

Research output: Contribution to journalArticle

Abstract

Objectives: To evaluate resource utilization and related costs in the management of hemophilic patients with Factor VIII inhibitors. Methods: A systematic literature review was performed to identify studies that evaluated costs of the management of severe hemophilic patients with inhibitors from January 1998 to June 2005. Results: 26 papers meeting search criteria were found. Selected papers were examined and articles having no relevance to economic aspects were excluded as well as review articles; of the ten remaining papers, three were full economic evaluations and seven were cost-analyses. Most studies evaluated the economic burden of treating patients with inhibitors with an on-demand regimen. Two modelling studies were aimed at assessing lifetime costs and outcomes of the immune tolerance (ITI) approach to Factor VIII inhibitors eradication. Conclusions: Observational, non-controlled studies reported high treatment costs for inhibitors patients, while case-control experiences highlight that excess costs may be due to a minority of patients. This conflicting evidence makes the assessment of the optimal inhibitor treatment a difficult one. ITI treatment resulted in better outcomes, in terms of survival and quality-adjusted survival, at lower costs than on-demand treatment, when projected lifetime; ITI requires an initial prominent investment but, due to the high success rate, it allows a subsequent cost reduction in most subjects. Given the limited healthcare resources, a priority setting policy for ITI should consider the careful identification of clinical and non-clinical predictors of future medical needs and costs of hemophilic patients with inhibitors.

Original languageItalian
Pages (from-to)33-44
Number of pages12
JournalPharmacoEconomics - Italian Research Articles
Volume8
Issue number1
Publication statusPublished - 2006

Fingerprint

Hemophilia A
Economics
Costs and Cost Analysis
Factor VIII
Immune Tolerance
Survival
Health Care Costs
Cost-Benefit Analysis
Therapeutics
Delivery of Health Care

ASJC Scopus subject areas

  • Pharmacology
  • Health Policy

Cite this

Implicazioni economiche del trattamento dei pazienti emofilici con inibitori : Una revisione sistematica della letteratura. / Negrini, Cristina; Daniele, F.; Mancuso, M. E.; Rivolta, G. F.; Tagliaferri, A.

In: PharmacoEconomics - Italian Research Articles, Vol. 8, No. 1, 2006, p. 33-44.

Research output: Contribution to journalArticle

@article{eb45179f6d6647e9a10440b15e4d78d9,
title = "Implicazioni economiche del trattamento dei pazienti emofilici con inibitori: Una revisione sistematica della letteratura",
abstract = "Objectives: To evaluate resource utilization and related costs in the management of hemophilic patients with Factor VIII inhibitors. Methods: A systematic literature review was performed to identify studies that evaluated costs of the management of severe hemophilic patients with inhibitors from January 1998 to June 2005. Results: 26 papers meeting search criteria were found. Selected papers were examined and articles having no relevance to economic aspects were excluded as well as review articles; of the ten remaining papers, three were full economic evaluations and seven were cost-analyses. Most studies evaluated the economic burden of treating patients with inhibitors with an on-demand regimen. Two modelling studies were aimed at assessing lifetime costs and outcomes of the immune tolerance (ITI) approach to Factor VIII inhibitors eradication. Conclusions: Observational, non-controlled studies reported high treatment costs for inhibitors patients, while case-control experiences highlight that excess costs may be due to a minority of patients. This conflicting evidence makes the assessment of the optimal inhibitor treatment a difficult one. ITI treatment resulted in better outcomes, in terms of survival and quality-adjusted survival, at lower costs than on-demand treatment, when projected lifetime; ITI requires an initial prominent investment but, due to the high success rate, it allows a subsequent cost reduction in most subjects. Given the limited healthcare resources, a priority setting policy for ITI should consider the careful identification of clinical and non-clinical predictors of future medical needs and costs of hemophilic patients with inhibitors.",
author = "Cristina Negrini and F. Daniele and Mancuso, {M. E.} and Rivolta, {G. F.} and A. Tagliaferri",
year = "2006",
language = "Italian",
volume = "8",
pages = "33--44",
journal = "PharmacoEconomics - Italian Research Articles",
issn = "1590-9158",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Implicazioni economiche del trattamento dei pazienti emofilici con inibitori

T2 - Una revisione sistematica della letteratura

AU - Negrini, Cristina

AU - Daniele, F.

AU - Mancuso, M. E.

AU - Rivolta, G. F.

AU - Tagliaferri, A.

PY - 2006

Y1 - 2006

N2 - Objectives: To evaluate resource utilization and related costs in the management of hemophilic patients with Factor VIII inhibitors. Methods: A systematic literature review was performed to identify studies that evaluated costs of the management of severe hemophilic patients with inhibitors from January 1998 to June 2005. Results: 26 papers meeting search criteria were found. Selected papers were examined and articles having no relevance to economic aspects were excluded as well as review articles; of the ten remaining papers, three were full economic evaluations and seven were cost-analyses. Most studies evaluated the economic burden of treating patients with inhibitors with an on-demand regimen. Two modelling studies were aimed at assessing lifetime costs and outcomes of the immune tolerance (ITI) approach to Factor VIII inhibitors eradication. Conclusions: Observational, non-controlled studies reported high treatment costs for inhibitors patients, while case-control experiences highlight that excess costs may be due to a minority of patients. This conflicting evidence makes the assessment of the optimal inhibitor treatment a difficult one. ITI treatment resulted in better outcomes, in terms of survival and quality-adjusted survival, at lower costs than on-demand treatment, when projected lifetime; ITI requires an initial prominent investment but, due to the high success rate, it allows a subsequent cost reduction in most subjects. Given the limited healthcare resources, a priority setting policy for ITI should consider the careful identification of clinical and non-clinical predictors of future medical needs and costs of hemophilic patients with inhibitors.

AB - Objectives: To evaluate resource utilization and related costs in the management of hemophilic patients with Factor VIII inhibitors. Methods: A systematic literature review was performed to identify studies that evaluated costs of the management of severe hemophilic patients with inhibitors from January 1998 to June 2005. Results: 26 papers meeting search criteria were found. Selected papers were examined and articles having no relevance to economic aspects were excluded as well as review articles; of the ten remaining papers, three were full economic evaluations and seven were cost-analyses. Most studies evaluated the economic burden of treating patients with inhibitors with an on-demand regimen. Two modelling studies were aimed at assessing lifetime costs and outcomes of the immune tolerance (ITI) approach to Factor VIII inhibitors eradication. Conclusions: Observational, non-controlled studies reported high treatment costs for inhibitors patients, while case-control experiences highlight that excess costs may be due to a minority of patients. This conflicting evidence makes the assessment of the optimal inhibitor treatment a difficult one. ITI treatment resulted in better outcomes, in terms of survival and quality-adjusted survival, at lower costs than on-demand treatment, when projected lifetime; ITI requires an initial prominent investment but, due to the high success rate, it allows a subsequent cost reduction in most subjects. Given the limited healthcare resources, a priority setting policy for ITI should consider the careful identification of clinical and non-clinical predictors of future medical needs and costs of hemophilic patients with inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=33846794465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846794465&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:33846794465

VL - 8

SP - 33

EP - 44

JO - PharmacoEconomics - Italian Research Articles

JF - PharmacoEconomics - Italian Research Articles

SN - 1590-9158

IS - 1

ER -